JNJ 108.68 Johnson & Johnson $JNJ Hit a 52 week high of 109.06 Closing the day 09:45 at 108.68 -0.39 -0.36% With a day low of 108.62 and a total volume of 344,099.
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Stock Market Today: Stocks Flat as Retail Sales Counter Eurozone Growth Woes
at The Street - 37 mins ago
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 38.99 (-2.86), JNJ: 108.39 (-0.68), HTZ: 20.02 (-2.71), VA: 30.37 (+30.37), GERN: 2.86 (+0.55), JWN: 74.17 (+0.92)
Early Glance: Medical Devices companies
AP - 2 hrs 14 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 109.93 (-0.68), JNJ: 108.39 (-0.68), MDT: 69.10 (-0.28), BAX: 71.87 (-0.21)
Early Glance: Pharmaceuticals companies
AP - 2 hrs 14 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.39 (-0.68), BAX: 71.87 (-0.21), PFE: 30.31 (-0.11), BMY: 57.79 (-0.01)
Setting Up A Portfolio That Millennials Can Relate To
FinancialDave - at Seeking Alpha - 2 hrs 56 mins ago
JNJ: 108.39 (-0.68), VTV: 83.80 (+0.03), SPY: 204.17 (-0.02)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 108.39 (-0.68), EW: 124.26 (-0.29)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.39 (-0.68), ABT: 43.97 (-0.62), DHR: 82.25 (-0.15), MR: 31.35 (+0.13)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.39 (-0.68), GILD: 102.06 (-2.14), MRK: 58.88 (-0.66), ABBV: 63.69 (+0.06)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.39 (-0.68), PFE: 30.31 (-0.11), ABBV: 63.69 (+0.06)
ADHD drug hits FDA trouble
at Investor's Business Daily - Thu Nov 13, 5:37PM CST
Drugmaker Mallinckrodt (MNK) said that the FDA is no longer recognizing its generic ADHD drug, methylphenidate ER, as an equivalent to Johnson & Johnson's (JNJ) Concerta and is reclassifying the treatment as "therapeutically inequivalent."...
MNK: 86.50 (-0.46), JNJ: 108.39 (-0.68)
Final Glance: Pharmaceuticals companies
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.39 (-0.68), BAX: 71.87 (-0.21), PFE: 30.31 (-0.11), BMY: 57.79 (-0.01)
Final Glance: Medical Devices companies
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 109.93 (-0.68), JNJ: 108.39 (-0.68), MDT: 69.10 (-0.28), BAX: 71.87 (-0.21)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.39 (-0.68), AZN: 72.75 (-1.78), AMGN: 157.81 (-3.04), AMAG: 34.16 (-0.08)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.68 (-0.54), JNJ: 108.39 (-0.68), BCRX: 9.92 (-0.47), NAVB: 1.11 (+0.01), CMRX: 32.05 (-0.87), SRPT: 14.98 (-0.21), NBS: 6.15 (+0.76), TKMR: 16.34 (+0.07), GSK: 45.69 (+0.03), CEMP: 13.75 (-0.41), OMER: 19.06 (-0.51)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.70 (-0.09), JNJ: 108.39 (-0.68), ABT: 43.97 (-0.62), LMT: 186.29 (-1.68), KMB: 113.07 (-1.00), TGT: 68.02 (+0.52), WMT: 82.61 (-0.33), MCD: 96.24 (+0.76), PG: 88.43 (-0.17), CL: 67.85 (-0.44)
Johnson & Johnson Seeks Further Expansion, As China Opens Its Doors To Foreign Investment
Don Dion - at Seeking Alpha - Thu Nov 13, 2:35PM CST
JNJ: 108.39 (-0.68)
Mallinckrodt shares slide as FDA reclassifies drug
By The Associated Press - AP - Thu Nov 13, 1:45PM CST
Mallinckrodt will re-evaluate its fiscal 2015 forecast after the Food and Drug Administration said it is concerned that the company's generic ADHD drug is not equivalent to the brand-name drug it is based on. Mallinckrodt's U.S.-traded shares slid.
JNJ: 108.39 (-0.68)
This Billion Dollar Fund Manager is Betting Big on IBM Stock
Tim Brugger, The Motley Fool - Motley Fool - Thu Nov 13, 1:00PM CST
Billing itself as "the largest financial services group in Northern Europe," Sweden-based Nordea has a host of diversified banking operations, including managing approximately $25 billion under its Nordea Investment Management unit. As has been the...
JNJ: 108.39 (-0.68), IBM: 163.98 (+1.19), MSFT: 49.70 (+0.09)
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Stock Market Today: Stocks Flat as Retail Sales Counter Eurozone Growth Woes
at The Street - 37 mins ago
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 38.99 (-2.86), JNJ: 108.39 (-0.68), HTZ: 20.02 (-2.71), VA: 30.37 (+30.37), GERN: 2.86 (+0.55), JWN: 74.17 (+0.92)
Early Glance: Medical Devices companies
AP - 2 hrs 14 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 109.93 (-0.68), JNJ: 108.39 (-0.68), MDT: 69.10 (-0.28), BAX: 71.87 (-0.21)
Early Glance: Pharmaceuticals companies
AP - 2 hrs 14 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.39 (-0.68), BAX: 71.87 (-0.21), PFE: 30.31 (-0.11), BMY: 57.79 (-0.01)
Setting Up A Portfolio That Millennials Can Relate To
FinancialDave - at Seeking Alpha - 2 hrs 56 mins ago
JNJ: 108.39 (-0.68), VTV: 83.80 (+0.03), SPY: 204.17 (-0.02)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 108.39 (-0.68), EW: 124.26 (-0.29)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.39 (-0.68), ABT: 43.97 (-0.62), DHR: 82.25 (-0.15), MR: 31.35 (+0.13)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.39 (-0.68), GILD: 102.06 (-2.14), MRK: 58.88 (-0.66), ABBV: 63.69 (+0.06)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.39 (-0.68), PFE: 30.31 (-0.11), ABBV: 63.69 (+0.06)
ADHD drug hits FDA trouble
at Investor's Business Daily - Thu Nov 13, 5:37PM CST
Drugmaker Mallinckrodt (MNK) said that the FDA is no longer recognizing its generic ADHD drug, methylphenidate ER, as an equivalent to Johnson & Johnson's (JNJ) Concerta and is reclassifying the treatment as "therapeutically inequivalent."...
MNK: 86.50 (-0.46), JNJ: 108.39 (-0.68)
Final Glance: Pharmaceuticals companies
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.39 (-0.68), BAX: 71.87 (-0.21), PFE: 30.31 (-0.11), BMY: 57.79 (-0.01)
Final Glance: Medical Devices companies
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 109.93 (-0.68), JNJ: 108.39 (-0.68), MDT: 69.10 (-0.28), BAX: 71.87 (-0.21)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.39 (-0.68), AZN: 72.75 (-1.78), AMGN: 157.81 (-3.04), AMAG: 34.16 (-0.08)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.39 (-0.68), GERN: 2.87 (+0.56)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.68 (-0.54), JNJ: 108.39 (-0.68), BCRX: 9.92 (-0.47), NAVB: 1.11 (+0.01), CMRX: 32.05 (-0.87), SRPT: 14.98 (-0.21), NBS: 6.15 (+0.76), TKMR: 16.34 (+0.07), GSK: 45.69 (+0.03), CEMP: 13.75 (-0.41), OMER: 19.06 (-0.51)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.70 (-0.09), JNJ: 108.39 (-0.68), ABT: 43.97 (-0.62), LMT: 186.29 (-1.68), KMB: 113.07 (-1.00), TGT: 68.02 (+0.52), WMT: 82.61 (-0.33), MCD: 96.24 (+0.76), PG: 88.43 (-0.17), CL: 67.85 (-0.44)
Johnson & Johnson Seeks Further Expansion, As China Opens Its Doors To Foreign Investment
Don Dion - at Seeking Alpha - Thu Nov 13, 2:35PM CST
JNJ: 108.39 (-0.68)
Mallinckrodt shares slide as FDA reclassifies drug
By The Associated Press - AP - Thu Nov 13, 1:45PM CST
Mallinckrodt will re-evaluate its fiscal 2015 forecast after the Food and Drug Administration said it is concerned that the company's generic ADHD drug is not equivalent to the brand-name drug it is based on. Mallinckrodt's U.S.-traded shares slid.
JNJ: 108.39 (-0.68)
This Billion Dollar Fund Manager is Betting Big on IBM Stock
Tim Brugger, The Motley Fool - Motley Fool - Thu Nov 13, 1:00PM CST
Billing itself as "the largest financial services group in Northern Europe," Sweden-based Nordea has a host of diversified banking operations, including managing approximately $25 billion under its Nordea Investment Management unit. As has been the...
JNJ: 108.39 (-0.68), IBM: 163.98 (+1.19), MSFT: 49.70 (+0.09)
